Ipragliflozin Impurity 5；1922933-61-6

• 
  

• Product Information

• Product Number: I010005

• English Name: Ipragliflozin Impurity 5

• English Alias: (3R,4S,5S,6R)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol

• CAS Number: 1922933-61-6

• Molecular Formula: C??H??FO?S

• Molecular Weight: 420.45

• Advantages

• As an impurity of Ipragliflozin, this compound has the following advantages:
• 
  

• Well-defined with multiple chiral centers: Contains (3R,4S,5S,6R) tetrachiral pyranose ring, 3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl side chain, and tetraol substituents. Unlike ipragliflozin (SGLT2 inhibitor with glucose-mimetic structure), its thiophene hydrophobicity, fluorine electronegativity, and polyhydroxyl hydrophilicity create significant differences, enabling precise differentiation via HPLC/HILIC as a specific marker;

• High stability and traceability: Rigid pyranose structure and stability of benzothiophene/hydroxyls ensure neutral-condition stability. As a byproduct from incomplete pyranose hydroxylation or chiral deviation in synthesis, it directly reflects glycosylation efficiency, improving process tracing accuracy;

• High detection sensitivity: Conjugated benzothiophene-benzene shows strong UV absorption (230-260nm), combined with m/z 421 [M+H]? enabling ppb-level analysis via LC-MS, compatible with SGLT2 inhibitor pyranose impurity systems.

• Applications

• Pharmaceutical quality control: Used as an impurity reference standard to quantify Ipragliflozin Impurity 5 in APIs, ensuring residual glycosylation byproducts meet quality standards;

• Synthesis optimization: Optimizing pyranose hydroxylation (oxidant selectivity) by monitoring impurity levels to reduce incompletely hydroxylated intermediates;

• Intermediate purity assessment: Evaluating purity of key glycosyl-aryl coupling intermediates in ipragliflozin synthesis to support chiral resolution and hydroxyl protection steps.

• Background Description

• Ipragliflozin’s activity relies on glucose-mimetic binding to SGLT2, synthesized via aryl-pyranose coupling and multi-step hydroxylation. Incomplete hydroxylation or chiral deviation may generate tetraol pyranose derivatives like Ipragliflozin Impurity 5. With altered binding efficiency, its residues risk reducing ipragliflozin purity, making control critical for quality assurance.

• Research Status

• Current research focuses on:
• 
  

• Analytical method validation: Developing HILIC assays with amino columns for separation, achieving 0.1 ppb detection limits;

• Glycosylation kinetics: Studying impurity formation under varying coupling reagents to clarify hydroxylation-chirality correlation;

• Process refinement: Controlling impurity levels below 0.1% via optimized hydroxylation parameters to enhance API purity;

• Structural confirmation: Using 1H/13C/1?F-NMR to verify pyranose chirality and substituent positions, distinguishing from ipragliflozin for authoritative identification.

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com